Liver function tests

MarketAxess Announces First Casada Trade Via RFQ

Retrieved on: 
星期二, 三月 12, 2024
Professional Services, Finance, Long time no see, MarketAxess, Liver function tests, RFQ, NTN, ADV, LATAM, Market, Emerging market, Security (finance)

MarketAxess Holdings Inc. (Nasdaq: MKTX), the operator of a leading electronic trading platform for fixed-income securities, today announced the first client Casada trade executed via Request-for-Quote (RFQ) protocol on their Emerging Markets (EM) platform, with Safra as the buyside client.

Key Points: 
  • MarketAxess Holdings Inc. (Nasdaq: MKTX), the operator of a leading electronic trading platform for fixed-income securities, today announced the first client Casada trade executed via Request-for-Quote (RFQ) protocol on their Emerging Markets (EM) platform, with Safra as the buyside client.
  • MarketAxess now provides trading in the complete spectrum of Brazilian sovereign debt instruments – including LFTs, LTNs, NTN-Fs and NTN-Bs.
  • As the dominant protocol for fixed income electronic trading globally, the introduction of trading Casada via RFQ by MarketAxess supports greater liquidity discovery for local and international investors trading Brazilian debt strategies.
  • “We are extremely proud that we were able to support the first-ever Casada trade via RFQ,” said Maria Calderon, Head of Latin America Sales at MarketAxess.

Alveo Technologies Is Developing Groundbreaking Avian Influenza Molecular Test for Poultry in Partnership with x-OvO, Royal GD, and Pharmsure

Retrieved on: 
星期二, 一月 9, 2024
David Gal, Farmer, Health, Knowledge, Food security, Royal, Risk, Pandemic, WHO, Disease, Laboratory, Liver function tests, LAMP, Data collection, PCR, Infection, Group A, WOAH, Diagnosis, Bird, Vaccine

ALAMEDA, Calif., Jan. 9, 2024 /PRNewswire/ -- Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with its proprietary be.well technology platform, today announced it is working with experts and leaders in the poultry industry to launch a rapid, accurate, in-the-field multiplex panel to test for all relevant strains of avian influenza, initially focusing on Group A, H5, H7, and H9. To help codevelop and distribute the tests, Alveo has partnered with industry leaders x-OvO, Royal GD, and Pharmsure International Ltd. The company expects to release their first product in the poultry diagnostic space, in EMEA in the first half of 2024.  

Key Points: 
  • To help codevelop and distribute the tests, Alveo has partnered with industry leaders x-OvO, Royal GD, and Pharmsure International Ltd.
  • The avian flu test will be Alveo's first product to launch into the agricultural sector since Alveo announced its open platform and partnering strategy last year.
  • In addition to avian flu, Alveo is partnering to develop test panels for many other pathogens impacting the agriculture industry.
  • "We've been working closely with Alveo in a deep collaboration to develop these highly valuable assays for Avian Influenza," said Wim Kieftenbeld, Director Business Development at Royal GD.

GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions

Retrieved on: 
星期四, 十月 5, 2023
Consultant, Injury, HIV disease progression rates, Frontiers, Biomarker, NKT, Doctor of Philosophy, Osteopontin, Natural killer T cell, School, Inflammation, Manuscript, IPF, Alcoholic hepatitis, Saint Vincent, Disease, NASH, GRI, Fibroblast, Teaching hospital, IL-6, Idiopathic pulmonary fibrosis, Rheumatoid arthritis, Movement, Liver function tests, St. Vincent's University Hospital, Oxygen, LA, Lupus nephritis, Lupus, Medical school, Associate, Multiple sclerosis, University College Dublin, Fibrosis, Tissue, NK, Macrophage, Human, Cytokine, Chemokine, Patient, Neutrophil, Vaccine, Pharmaceutical industry, Medicine

LA JOLLA, CA, Oct. 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the publication of an article that reviews data in both experimental models and in humans that suggest a key role of type 1 invariant NKT (iNKT) cell activation in the progression of inflammatory cascades leading to recruitment of neutrophils and activation of the inflammasome, macrophages, fibroblasts, and, ultimately, fibrosis. The manuscript titled, “Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis,” has been published in Frontiers in Immunology.1

Key Points: 
  • iNKT are pro-inflammatory effector T cells that accumulate in many models of chronic fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), lupus nephritis and NASH.
  • I am encouraged by the emerging experimental evidence that iNKT cells play an important role in chronic inflammation and fibrosis.
  • iNKT cells are involved in the regulation of all three, type 1, type 2 and type 3 cytokine associated fibrotic pathways.
  • GRI Bio’s lead program, GRI-0621 is a small molecule RAR-βɣ dual agonist that inhibits the activity of human type 1, iNKT cells.

GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期一, 八月 14, 2023
Insurance, Patent, Injury, Oxygen, Overalls, NKT, IL-6, Research, SLE, Inflammation, Lupus, Doctor of Philosophy, Movement, Mergers and acquisitions, Fibrosis, Type 2, GRI, Patient, Autoimmune disease, Immune system, Lupus nephritis, CFO, LA, Cytokine, IPF, Liver function tests, IND, Natural killer T cell, Autoantibody, Pharmaceutical industry, Vaccine, Birth control, Cryptocurrency

LA JOLLA, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • “The past quarter was marked by a number of critical advancements on both the clinical and corporate sides of our business.
  • This study will evaluate our lead program, GRI-0621 for the treatment of IPF, an Orphan indication in need of innovative solutions.
  • GRI Bio’s second asset in development, GRI-0803, is a novel activator of human Type 2 NKT cells.
  • As of June 30, 2023, the Company had cash and cash equivalents of approximately $4.8 million.

GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio

Retrieved on: 
星期二, 六月 27, 2023
Patent, Retinoic acid, United States Patent and Trademark Office, NKT, IP, Retinoic acid receptor, Fibrosis, GRI, Patient, LA, IPF, Liver function tests, Natural killer T cell, Idiopathic pulmonary fibrosis, RAR, Pharmaceutical industry

LA JOLLA, CA, June 27, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today provided an update to the progress of its patent portfolio development.

Key Points: 
  • - U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic pulmonary fibrosis (IPF)
    LA JOLLA, CA, June 27, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today provided an update to the progress of its patent portfolio development.
  • Most recently, the Company received notice that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
  • 11,660,309 entitled, “Prevention and treatment of inflammatory conditions,” covering methods for the prevention and treatment of inflammatory conditions.
  • We are pleased to have been issued this latest U.S. patent for GRI-0621 which extends our patent coverage to 2032 and which we believe provides further validation of our differentiated approach.

GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website

Retrieved on: 
星期二, 六月 13, 2023
Injury, Liver function tests, NKT, SLE, Inflammation, Multiple sclerosis, Doctor of Philosophy, Inflammatory bowel disease, Fibrosis, GRI, Patient, LA, IPF, Natural killer T cell, Idiopathic pulmonary fibrosis, Pharmaceutical industry

LA JOLLA, CA, June 13, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced its new corporate branding and launch of its new corporate website, gribio.com.

Key Points: 
  • We remain committed to advancing our leading NKT platform technology, which we believe holds an opportunity for all stakeholders as well as the potential for significant value creation.
  • We are excited to take this next step in the evolution of our Company and position ourselves to unlock further potential,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
  • GRI Bio plans to leverage the 505(b)(2) regulatory pathway to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF, expected to commence in the second half of 2023.
  • Additionally, with a library of over 500 proprietary compounds, GRI has the potential to fuel a growing pipeline.

GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators

Retrieved on: 
星期一, 五月 22, 2023
Injury, Week, Serum, Oxygen, Overalls, Aes, NKT, Pharmacokinetics, IL-6, Bronchoalveolar lavage, SLE, Inflammation, Biomarker, Lupus, Multiple sclerosis, Doctor of Philosophy, Movement, Rheumatoid arthritis, Inflammatory bowel disease, Fibrosis, BAL, Type 2, GRI, HIV disease progression rates, Patient, Blood, Autoimmune disease, Immune system, Lupus nephritis, LA, Cytokine, IPF, Liver function tests, Natural killer T cell, ALS, Autoimmunity, Safety, Autoantibody, Pharmaceutical industry, Vaccine

LA JOLLA, CA, May 22, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today provided a business outlook and highlighted upcoming milestones for its innovative pipeline of NKT cell modulators in development.

Key Points: 
  • Rapidly advancing clinical pipeline in potential high-value inflammatory, fibrotic and autoimmune diseases
    LA JOLLA, CA, May 22, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today provided a business outlook and highlighted upcoming milestones for its innovative pipeline of NKT cell modulators in development.
  • “We believe our leading NKT platform technology represents a compelling opportunity with the potential for significant value creation.
  • GRI Bio’s lead program, GRI-0621 is a small molecule RAR-βɣ dual agonist that inhibits the activity of human Type I, iNKT cells.
  • GRI Bio’s second asset in development, GRI-0803, is a novel activator of human Type 2 NKT cells.

Global Hepatic Encephalopathy Therapeutics Market Report 2023: Players Include Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline and Pfizer - ResearchAndMarkets.com

Retrieved on: 
星期三, 四月 19, 2023
Health, Pharmaceutical, Myenteric plexus, Seizure, Rifaximin, Hepatitis, Liver function tests, Therapy, Prevalence, Probiotic, Liver, Liver disease, Public, Anxiety, NORD, USFDA, Hepatic encephalopathy, Lactulose, Nutrient, Brain, National Organ Transplant Act of 1984, Thiamine, Acute liver failure, Plasma, Rare, Acetic acid, Patient, Ammonia, Lethargy, Confusion, Diagnosis, Personality, Cirrhosis, Disease, Vaccine, Dietary supplement

If effectively diagnosed, hepatic encephalopathy occurs in almost two-thirds of the patients suffering from liver cirrhosis.

Key Points: 
  • If effectively diagnosed, hepatic encephalopathy occurs in almost two-thirds of the patients suffering from liver cirrhosis.
  • Hepatic encephalopathy is categorized into 3 types Type A (acute liver failure), Type B (portal systemic bypass without liver disease), and Type C (liver cirrhosis).
  • The clinical manifestation associated with hepatic encephalopathy is confusion, anxiety, lethargy, seizures, confused speech, personality changes, and poor body movements.
  • In 2010 the USFDA approved Rifaximin for the treatment of hepatic encephalopathy by acting on the microorganisms in the intestinal tract producing ammonia.

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Retrieved on: 
星期三, 三月 22, 2023
Insurance, AACR, Liver function tests, CD3, Survival, Lonza, Clinical trial, LFT, Path integral molecular dynamics, Anastrozole, G&A, Research, CLDN6, Immunotherapy, Lung, American Association for Cancer Research, Patient, Immune system, Cancer, Context, Growth, R, IND, Female, Breast cancer, Pharmaceutical industry, Cryptocurrency, Vaccine, Fine chemical

PHILADELPHIA, March 22, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced financial results for the year ended December 31, 2022. Additionally, the Company announced a portfolio prioritization and capital allocation strategy that is expected to extend its cash runway into late 2024. The resulting changes include discontinuing the development of onapristone extended release (ONA-XR) and focusing on the development of CTIM-76, its Claudin 6 (CLDN6) bispecific antibody clinical candidate.

Key Points: 
  • PHILADELPHIA, March 22, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced financial results for the year ended December 31, 2022.
  • “We are shifting our development focus to our compelling preclinical asset CTIM-76, a CLDN6 x CD3 bispecific antibody.
  • ET, Context will host an investor R&D webinar with the Company’s management team and AACR presenter to discuss the presentation.
  • Context reported a net loss of $14.8 million for 2022, as compared to $10.5 million for the same period in 2021.

Long Fiber Thermoplastics Market Report 2022: Increasing Demand from Automotive, Aerospace and Electronics Industries Drives Growth - ResearchAndMarkets.com

Retrieved on: 
星期一, 一月 30, 2023
Other Manufacturing, Manufacturing, IEA, Ether, Process, Carbon, Liver function tests, Electric vehicle industry in China, European Automobile Manufacturers Association, USD, EVS, Growth, ACEA, Car, Weight, International Energy Agency, Thermoplastic, Polyamide

The global long fiber thermoplastics market size is anticipated to reach USD 9.3 billion by 2030.

Key Points: 
  • The global long fiber thermoplastics market size is anticipated to reach USD 9.3 billion by 2030.
  • Increasing demand for lightweight materials with high strength in the automotive, aerospace, and electrical & electronics industry is expected to propel the demand for long-fiber thermoplastics.
  • The growth of this segment can be attributed to the increasing demand for glass fiber thermoplastics in the automotive industry.
  • The new product is made of regenerated cellulose fibers, it provides weight reduction and mechanical strength which helps manufacturers to reduce their carbon footprint and meet sustainability
    Chapter 3 Long Fiber Thermoplastics Market: Variables, Trends & Scope
    Chapter 4 Long Fiber Thermoplastics Market: Resin Type Estimates & Trend Analysis
    4.1 Global Long Fiber Thermoplastics Market: Resin Type Movement Analysis & Market Share, 2021 & 2030